What does BPC-157 do?

The source identifies BPC-157 as a synthetic peptide with 15 amino-acid residues and links it to a protein fragment associated with human gastric juice. It describes research mainly in animal models involving tendon, ligament, gastrointestinal, and other tissue-injury contexts; this does not establish clinical benefit.

How does BPC-157 work?

The supplied entry proposes involvement of VEGFR2-associated angiogenesis, nitric-oxide signaling through Akt-eNOS, anti-inflammatory activity, and growth-factor signaling. It also states that a direct molecular target has not been definitively identified and that much of this work comes from rodents.

What is the typical dose of BPC-157?

The record contains a community-reported 250-500 mcg twice daily entry with 1-2x daily frequency and a 200-1,000 mcg per day total range. It also records subcutaneous administration near an injury site, or systemic administration. These are source data, not clinical dosing guidance.

Healing Clinical Trials - human trials under way

BPC-157

Also known as: Body Protection Compound-157, Pentadecapeptide BPC 157

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

A synthetic 15-residue peptide with predominantly preclinical healing research.

Status

Clinical Trials

Evidence level: human studies

Typical dose

250–500mcg

Subcutaneous injection near injury site

Researched for

Injury recovery, gut healing, joint and tendon repair

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Phase II - Emerging human evidence with important limitations

Use the tools

In plain language

A synthetic 15-residue listed as BPC-157.
The supplied source describes predominantly animal research in injury-recovery, gastrointestinal, joint, tendon, and tissue models.
Human evidence is described as limited, and the source's regulatory statements were not independently verified.

How it's thought to work

The supplied source describes several proposed pathways: -linked , nitric-oxide signaling involving Akt-, anti-inflammatory effects, and growth-factor signaling. It frames these as predominantly rodent findings and reports that the precise molecular target remains unresolved. These mechanistic claims require corroboration.

What the research shows

Where the research stands

According to the supplied account of a 2025 Biomedicines narrative review, the record includes hundreds of animal studies across tendon, muscle, bone, gastrointestinal, liver, and nervous-system models, but only three human pilot reports: knee-pain injection, bladder injection for interstitial cystitis, and intravenous safety. The same account reports no completed randomized controlled human trials and no regulatory approval. It further describes rapid breakdown into amino-acid fragments and a sub-30 minute elimination after injection in rats and dogs, leaving oral delivery uncertain. These claims require independent corroboration.

What it shows

✓ Human studies

Emerging human evidence with important limitations

△ Limitations

Study protocols describe research and are not dosing recommendations.

Bottom line: Phase 2 recruiting (NCT07437547); investigational. Not FDA approved; investigational.

Typical dosing

CommunityCommunity dataset

250–500 mcg

twice daily

200 mcg/dayfull range seen1,000 mcg/day

The community description reports localized or systemic use and commonly divides entries between morning and evening.

Research dosing

Study-specific protocolsHuman trials under way - protocols are study-specific

Doses observed in studies

250-500 mcg twice daily

Preclinical Research - Doses from animal/in-vitro studies

Study protocols describe research and are not dosing recommendations.

Duration: 4-12 weeks in most research protocols
Administration: Subcutaneous injection near injury site, or systemic

Timing & administration

Best time to take

Morning and evening (or near injury site timing)

1-2 times daily, consistent timing

Food recommendation

With or without food

Why this timing?

The source characterizes effects as systemic and says divided dosing may maintain levels; it also mentions activity timing in injury contexts. No validated human timing rationale was supplied.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well-tolerated in preclinical studies
Nausea
Dizziness
Injection site reactions
Fatigue
Headache
May trigger histamine release - use caution with MCAS or histamine sensitivity
Potential concern for tumor promotion (angiogenesis)
Limited long-term human safety data

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

No FDA approval is established by the supplied evidence. The source asserts that BPC-157 has no approval from any regulator, calls it "Preclinical - FDA Category 2," and says a stated April 15, 2026 HHS announcement could lead to Category 1 reclassification; it also says Category 2 remains in effect under current law pending a formal FDA rule, notes a July 23-24, 2026 PCAC review, and says formal FDA publication is pending. These regulatory assertions were not independently corroborated.

The source lists nausea, dizziness, injection-site reactions, fatigue, headache, possible histamine release, a potential angiogenesis-related tumor-promotion concern, and limited long-term human safety data. It describes preclinical tolerability as generally good and flags MCAS or histamine sensitivity; no frequencies, causality assessments, or independently verified human risk estimates were supplied.

Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on BPC‑157

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

BPC-157

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions